Produced in collaboration with hivandhepatitis.com
Published: 05 October 2015
Monday, October 5, 2015
New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment
New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment
Liz Highleyman
Produced in collaboration with hivandhepatitis.com
Published: 05 October 2015
A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta – EDP-239 – was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Diego, USA. Other researchers reported that HCV co-infection and progressive liver disease contribute to mortality among people with HIV, offering further evidence in support of prompt hepatitis C treatment.
Produced in collaboration with hivandhepatitis.com
Published: 05 October 2015
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment